Wells Fargo analyst Yanan Zhu lowered the firm’s price target on Metagenomi (MGX) to $16 from $20 on updated model assumption, while keeping an Overweight rating on the shares. The firm notes updated NHP data from the Hem A program demonstrate stable FVIII levels out to 19 months, boding well for a differentiated product profile and also providing preclinical validation for the secreted protein platform.
Elevate Your Investing Strategy:
- Take advantage of TipRanks Premium at 50% off! Unlock powerful investing tools, advanced data, and expert analyst insights to help you invest with confidence.
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
Read More on MGX:
- Metagenomi’s Promising Gene Editing Advancements and Strategic Growth Drive Buy Rating
- Metagenomi, Inc. Reports Q1 2025 Financial Results
- Metagenomi reports Q1 EPS (68c), consensus (51c)
- Metagenomi sees cash, equivalents supporting operations into 2027
- Metagenomi price target lowered to $7 from $14 at H.C. Wainwright